Literature DB >> 11550317

Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors.

T C Comas1, T Tai, D Kimmel, B W Scheithauer, P C Burger, D K Pearl, S D Jewell, A J Yates.   

Abstract

Immunohistochemical staining intensity for ganglioside GD1b was determined for 108 human neuroectodermal tumors. Most of the tissue elements that immunostained were tumor cells; only a few axons and occasional neurons reacted in some specimens. All pilocytic astrocytomas stained very positively, whereas none of the ependymomas and only 11% of primitive neuroectodermal tumors, 20% of glioblastomas, and 28% of anaplastic astrocytomas showed more than faint staining. A similar association between grade and immunostaining was seen in tumors containing an oligodendrogliomatous component, but reactivity was not as strong as in astrocytic tumors or primitive neuroectodermal tumors. Results of Cox regression showed significant associations between immunostaining intensity and survival for all cases taken together (P = 0.007); for the group consisting of astrocytomas, oligoastrocytomas, and oligodendrogliomas (P = 0.002); and for astrocytomas alone (P = 0.04). Results were also significant using a proportional hazards model controlling for patient age (all cases P = 0.005; astrocytomas only P = 0.02), but not when controlling for tumor grade. Our results indicate that immunohistochemical staining for GD1b is correlated with tumor grade and that it may be of prognostic utility in some primary human brain tumors, especially astrocytomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11550317      PMCID: PMC1920757          DOI: 10.1093/neuonc/1.4.261

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  3 in total

1.  IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal
Journal:  Cell Immunol       Date:  2018-02-02       Impact factor: 4.868

2.  Glioma growth inhibition by neurostatin and O-But GD1b.

Authors:  Beatriz Valle-Argos; Diego Gómez-Nicola; Manuel Nieto-Sampedro
Journal:  Neuro Oncol       Date:  2010-07-08       Impact factor: 12.300

Review 3.  Re-configuration of sphingolipid metabolism by oncogenic transformation.

Authors:  Anthony S Don; Xin Y Lim; Timothy A Couttas
Journal:  Biomolecules       Date:  2014-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.